Why hospital chains keep lining up for IPOs
Every few months, a hospital chain files papers for a public listing, and every time, the pitch sounds similar: India is under-bedded relative to its population, health insurance penetration is rising, and out-of-pocket medical spending is finally shifting toward organised, insured care. All of that is broadly true. But "healthcare demand is growing" is not the same as "this specific hospital chain will make you money." Those are two very different questions, and IPO prospectuses are written to blur the line between them.
Hospital businesses are capital-intensive, slow to scale, and deeply local. A chain that's dominant in one city can struggle to replicate that success two states away. Understanding why requires looking past the growth narrative and into how hospitals actually make money.
Occupancy and ARPOB: the two numbers that matter most
Two metrics decide whether a hospital chain is genuinely profitable or just growing its bed count: occupancy rate and ARPOB — average revenue per occupied bed. A hospital can have hundreds of beds, but if only 55-60% are occupied on a given day, a large share of fixed costs — staff salaries, equipment depreciation, facility maintenance — go unrecovered.
Mature, well-run hospital chains typically run occupancy above 65-70% in their established units, while newer facilities can take three to five years to reach similar levels. If an IPO prospectus shows several "new" or "under-development" hospitals as a large share of total capacity, model in a longer runway before those beds start contributing meaningfully to profit.
- Check occupancy trends over at least three years, not just the latest one
- Compare ARPOB growth to inflation — if it's barely keeping pace, pricing power is weak
- Separate mature hospital revenue from new-hospital revenue in the numbers
Payor mix: who's actually paying the bill
Not all hospital revenue is equal. Broadly, patients pay through three routes: out-of-pocket cash, private health insurance (TPA-routed), and government schemes like Ayushman Bharat or state health schemes. Government scheme reimbursements are typically the lowest-margin, often paid late and at rates hospitals consider unremunerative. A chain that leans heavily on government scheme patients for volume may show strong footfall but weak margins.
The healthier mix — and the one premium hospital chains tend to have — is a majority of revenue from insured, private-pay patients, particularly in specialties like cardiology, oncology and orthopaedics where procedures are high-value and elective. Look for the payor mix breakdown in the prospectus, and see how it has shifted over the last few years. A rising share of insured patients is a genuinely good sign; a rising share of government scheme patients, despite boosting reported patient volumes, is not automatically bullish for margins.
Specialty mix and doctor dependency
Hospitals don't earn evenly across departments. High-complexity specialties — cardiac surgery, oncology, transplants, robotic surgery — carry far higher margins than general medicine or maternity. A chain with a strong tertiary-care specialty mix in metro locations tends to have pricing power that a chain built mostly around secondary care in smaller towns doesn't.
There's also a less-discussed risk: doctor dependency. Star specialists — a renowned cardiac surgeon or oncologist — often bring patient volumes tied to their personal reputation rather than the hospital brand. If a handful of doctors account for a disproportionate share of high-margin procedures, their departure (to a competing hospital, or to start their own practice) can meaningfully dent revenue. Prospectuses rarely spell this out explicitly, but management commentary on "key medical talent retention" is worth reading closely.
Regulatory price caps: a risk unique to healthcare
Healthcare is one of the few sectors where the regulator can directly cap what a company charges customers. NPPA price ceilings on medical devices like stents and knee implants, state government caps on Covid-era treatment charges, and periodic scrutiny of hospital billing practices are all real precedents. These interventions typically come with little warning and can compress margins overnight on categories that were previously high-revenue.
This isn't a reason to avoid the sector, but it is a reason to build in a margin-of-safety when valuing a hospital stock — don't assume today's pricing structure is permanent. Diversified chains with multiple specialties and geographies tend to absorb such shocks better than single-specialty or single-city operators.
Debt, expansion plans and use of IPO proceeds
Building or acquiring a new hospital is expensive, and most chains fund expansion through a mix of debt and equity. Check how much of the IPO proceeds are earmarked for debt repayment versus new capacity — a listing used mainly to pay down existing borrowings tells a different story than one funding genuine expansion. Also check whether new hospitals are greenfield builds (slower to profitability, typically 5+ years) or brownfield acquisitions of existing, functioning hospitals (faster to contribute, but often bought at a premium).
Debt servicing costs on an expansion-heavy balance sheet can quietly eat into profits for years, even as revenue grows. Look at the debt-to-equity ratio and interest coverage alongside the growth numbers, not instead of them.
The bottom line for retail investors
A hospital IPO can be a genuinely good long-term holding — healthcare demand in India is structurally rising, and organised players are steadily gaining share from unorganised, standalone nursing homes. But the quality of that opportunity varies enormously between chains. Before applying, look past the "India needs more hospital beds" pitch and check occupancy trends, payor mix, specialty concentration, doctor dependency and debt levels. Those details, more than the sector story, will decide whether the stock performs after listing — not just on day one, but over the years that follow.
